Beijing, China

Sujing Li

USPTO Granted Patents = 5 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2025

where 'Filed Patents' based on already Granted Patents

5 patents (USPTO):

Title: **Sujing Li: Innovator in Anticancer Solutions**

Introduction

Sujing Li is an accomplished inventor based in Beijing, China, known for his significant contributions to the field of biomedicine. With a total of five patents to his name, Li is particularly recognized for his research focusing on KRAS mutant protein inhibitors, which hold potential in cancer therapy.

Latest Patents

Among Sujing Li's latest innovations is his invention related to KRAS mutant protein inhibitors. This invention encompasses a KRAS mutant protein inhibitor represented by a specific formula, alongside a composition containing this inhibitor and its applications. This groundbreaking work aims to provide more effective treatment options for patients with KRAS mutant cancers, which are often difficult to treat.

Career Highlights

Sujing Li is affiliated with Jacobio Pharmaceuticals Co., Ltd., where he utilizes his expertise to advance drug development focused on innovative cancer therapies. His work has been pivotal in expanding the understanding of KRAS mutations and their implications in treatment protocols.

Collaborations

Throughout his career, Sujing Li has collaborated with other prominent professionals in his field, including Amin Li and Peng Wang. These collaborations enhance the research environment and foster innovative solutions in the fight against cancer.

Conclusion

Sujing Li continues to push the boundaries of biomedical research with his inventions and collaborative efforts. His work in developing KRAS mutant protein inhibitors is a testament to his dedication and innovation in addressing critical health challenges. As he continues his work at Jacobio Pharmaceuticals Co., Ltd., the potential for his contributions to shape the future of cancer treatment remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…